KAZIA’S PAXALISIB SHOWS POSITIVE OVERALL SURVIVAL SIGNAL
IN PHASE II GLIOBLASTOMA STUDY
Overall survival (OS) of 17.7 months, vs. 12.7 months for existing standard of care
Longest-treated patient remains progression-free 19 months after diagnosis
Sydney, 7 April 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian
oncology-focused biotechnology company, is pleased to share positive interim data from its
ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common
and most aggressive form of primary brain cancer.
Key Points
• Interim analysis of Part A (escalation cohort) (n=9) showed median overall survival
(OS) of 17.7 months, representing a clinically meaningful extension of life when
compared to the 12.7 months associated with the existing standard of care,
temozolomide
• Interim analysis of all evaluable patients (Part A = 9; Part B = 21) shows median
progression-free survival (PFS) of 8.5 months, broadly in line with previous analysis,
and comparing favourably to the 5.3 months associated with temozolomide
• The longest-treated patient remains progression-free 19 months after diagnosis
• Approximately half the enrolled patients remain on drug and both OS and PFS figures
may further improve as the trial progresses toward conclusion
• Kazia expects to present further data in 2H CY2020 and final data in 1H CY2021
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia paxalisib Phase II interim data
Ann: Kazia paxalisib Phase II interim data, page-2
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online